Editorial: Toxicity Mechanism and Clinical Features of PD-1/PD-L1 Inhibitors in Treatment of Cancer, Volume I

• Xiangyi Kong,
• Ryan J Sullivan,
• Caisheng Wu,
• Lin Zhang,
• Lin Zhang,
• Lin Zhang,
• Yu Jiang

Affiliations

Xiangyi Kong

Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Ryan J Sullivan

Center for Melanoma, Massachusetts General Hospital Cancer Center, Harvard Medical School, Harvard University, Boston, MA, United States

Caisheng Wu

School of Pharmaceutical Sciences, Xiamen University, Xiamen, China

Lin Zhang

School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Lin Zhang

Melbourne School of Population and Global Health, The University of Melbourne, Carlton, VIC, Australia

Lin Zhang

Centre of Cancer Research, Victorian Comprehensive Cancer Centre Project, Melbourne, VIC, Australia

Yu Jiang

School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China